AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33959583
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (CG)
Trial: 33137599
Drug: Curcumin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin (500 mg three times daily)
Trial: 32949370
Drug: Brivaracetam (BRV)
DrugBank: Brivaracetam (DB05541)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Brivaracetam (BRV) 100 mg post-5-min intravenous infusion
Trial: 32949370
Drug: Brivaracetam (BRV)
DrugBank: Brivaracetam (DB05541)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Brivaracetam (BRV) 1500 mg post-15-min intravenous infusion
Trial: 32949370
Drug: Levetiracetam (LEV)
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam (LEV) 1500 mg post-15-min intravenous infusion
Trial: 32949370
Drug: Levetiracetam (LEV)
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam (LEV) 1500 mg post-5-min intravenous infusion
Trial: 35090638
Drug: 5 7mu;g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 7mu;g CoV2 preS dTM with AS03
Trial: 35090638
Drug: 10 7mu;g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 7mu;g CoV2 preS dTM with AS03
Trial: 35090638
Drug: 15 7mu;g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 7mu;g CoV2 preS dTM with AS03
Trial: 35101085
Drug: Montelukast 10
RxNorm normalized name: montelukast 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 10 mg daily for 6 months
Trial: 34078324
Drug: Emotion-Focused Treatment
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Emotion-Focused Treatment (EFT)
Trial: 32751522
Drug: Magnesium (500
RxNorm normalized name: magnesium gluconate 27 mg magnesium (500 mg) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium (500 mg/day)
Trial: 33656950
Drug: Arthroscopic surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthroscopic surgery with postoperative physical therapy (SPT)
Trial: 33656950
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy alone (PTA)
Trial: 35029879
Drug: MBSR therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBSR therapy
Trial: 36069630
Drug: Enriched pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enriched pain management (EPM) pathway integrating physical therapy and mindfulness
Trial: 32703548
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion strategy (haemoglobin, 90–110 g L−1)
Trial: 32703548
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion strategy (haemoglobin, 70–90 g L−1)
Trial: 32985946
Drug: Caffeine (3-mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (3-mg/kg bodyweight)
Trial: 32985946
Drug: Placebo (3-mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3-mg/kg bodyweight lactose)
Trial: 39284953
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (chemotherapy)
Trial: 32469183
Drug: Relugolix (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relugolix (120 mg orally once daily)
Trial: 37713020
Drug: Leuprolide (injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide (injections every 3 months)
Trial: 34908015
Drug: Low-iron formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-iron formula with added bovine lactoferrin (1.0 g/L)
Trial: 34908015
Drug: Standard formula
RxNorm normalized name: Standard formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard formula at 8 mg/L iron and no added lactoferrin (control formula)
Trial: 32203968
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplementation (50,000 IU weekly for 9 weeks)
Trial: 34446483
Drug: Community-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based intervention with integrated skin screening and SDR-PEP administration
Trial: 34446483
Drug: Health centre-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health centre-based intervention with integrated skin screening and SDR-PEP administration
Trial: 36199771
Drug: Microwave ablation
RxNorm normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Microwave ablation combined with anti-PD-1 monoclonal antibody
Trial: 36199771
Drug: Anti-PD-1 monoclonal
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-1 monoclonal antibody
Trial: 33607060
Drug: ACEi or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEi or ARB treatment (n=3601)
Trial: 33607060
Drug: No ACEi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No ACEi or ARB treatment (n=3601)
Trial: 32126990
Drug: ICMA (intracameral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICMA (intracameral combination of 2 mydriatics and 1 anesthetic)
Trial: 32126990
Drug: Topical regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical regimen (conventional treatment)
Trial: 37028614
Drug: Silicone breast
RxNorm normalized name: Tommee Tippee Silicone Breast Pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone breast implants
Trial: 34850368
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of sitagliptin phosphate/metformin hydrochloride tablets (50 mg/850 mg) under fasting conditions
Trial: 34850368
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (JANUMET®) under fasting conditions
Trial: 34850368
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of sitagliptin phosphate/metformin hydrochloride tablets (50 mg/850 mg) under fed conditions
Trial: 34850368
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (JANUMET®) under fed conditions
Trial: 36055332
Drug: Pegcetacoplan (1080
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegcetacoplan (1080 mg subcutaneously twice weekly)
Trial: 36055332
Drug: Pegcetacoplan monotherapy
RxNorm normalized name: Pegcetacoplan
DrugBank: Pegcetacoplan (DB16694)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pegcetacoplan monotherapy
Trial: 33434408
Drug: Ertugliflozin 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertugliflozin 25 mg (Cohort B)
Trial: 34762378
Drug: Acupuncture for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture for regulating spleen and stomach combined with aspirin enteric‐coated tablets
Trial: 34762378
Drug: Aspirin enteric‐coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin enteric‐coated tablets (100 mg once daily)
Trial: 32513836
Drug: pTVG-AR vaccine
RxNorm normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pTVG-AR vaccine with or without GM-CSF adjuvant
Trial: 32513836
Drug: pTVG-AR vaccine
RxNorm normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pTVG-AR vaccine
Trial: 35867853
Drug: Oral tianeptine
RxNorm normalized name: tianeptine
DrugBank: Tianeptine (DB09289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tianeptine (50 mg)
Trial: 35867853
Drug: Intravenous tianeptine
RxNorm normalized name: tianeptine
DrugBank: Tianeptine (DB09289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tianeptine (500 to 2000 ng/ml)
Trial: 34843346
Drug: Prolonged exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged exposure (PE) therapy, delivered in a massed format (daily sessions across 2 weeks)
Trial: 36306151
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (Liraglutide, Diet, Sitagliptin)
Trial: 32219359
Drug: Apabetalone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apabetalone (100 mg orally twice daily)
Trial: 32165032
Drug: Home-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based therapy (DVD)
Trial: 36128663
Drug: Tocilizumab (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (8 mg/kg intravenously) every 4 weeks for 24 weeks
Trial: 36128663
Drug: Tocilizumab (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (8 mg/kg intravenously)
Trial: 32735952
Drug: Acute hyperglycaemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute hyperglycaemia (mean blood glucose: 321 ± 29 mg/dL)
Trial: 32735952
Drug: Euglycaemia (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euglycaemia (mean blood glucose: 138 ± 34 mg/dL)
Trial: 33428583
Drug: Durvalumab (D)
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab (D) 1500 mg/tremelimumab (T) 75 mg (intravenously every 4 weeks without SBRT)
Trial: 33984151
Drug: Concurrent temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Concurrent temozolomide and radiotherapy followed by adjuvant temozolomide
Trial: 35562720
Drug: Mild anemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild anemia (Hb 10.0-11.0 g/dL)
Trial: 35562720
Drug: Moderate anemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate anemia (Hb 7.0-10.0 g/dL)
Trial: 35562720
Drug: Severe anemia
RxNorm normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Severe anemia (Hb < 7.0 g/dL)
Trial: 32860075
Drug: Anti-PD1 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anti-PD1 therapy (discontinued due to prolonged remission or unacceptable toxicity)
Trial: 32764081
Drug: Acupuncture (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture (one session of Western medical acupuncture treatment in addition to standard treatment)
Trial: 32764081
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment according to Norwegian guidelines
Trial: 34500081
Drug: Milrinone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milrinone (0.5 ?g/kg/min)
Trial: 34500081
Drug: Nitroglycerin (0.2-0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (0.2-0.5 ?g/kg/min)
Trial: 36476466
Drug: Intravenous ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketorolac postoperatively and 3 days of oral ketorolac on discharge
Trial: 36476466
Drug: Standard-of-care pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care pain protocol involving oxycodone-acetaminophen 5 to 325 on discharge
Trial: 34895160
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose citrate (4.5 mmol/L)
Trial: 34895160
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose citrate (2.5 mmol/L)
Trial: 32409981
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg IV tramadol
Trial: 32409981
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg IV morphine
Trial: 34001407
Drug: Cryotherapy (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryotherapy (80 minutes applied in addition to standard oral care)
Trial: 33072188
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (20 grams total, with a 15-minute loading dose followed by a 24-hour maintenance infusion)
Trial: 33072188
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered in the same manner as magnesium sulfate)
Trial: 33657760
Drug: Continuous intra‐articular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intra‐articular (IA) infusion analgesia
Trial: 34213086
Drug: Baseline Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline Treatment Expectancy Scale (TES)
Trial: 34000325
Drug: Dexmedetomidine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.5 μg.kg‐1
Trial: 34000325
Drug: Fentanyl 2
RxNorm normalized name: fentanyl 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 2 μg.kg‐1
Trial: 33261915
Drug: Immediate nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate nicotine reduction condition (0.4 mg/g nicotine cigarettes)
Trial: 33261915
Drug: Gradual nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gradual nicotine reduction condition (15.5 to 0.4 mg/g)
Trial: 33261915
Drug: Control condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control condition (15.5 mg/g)
Trial: 34392187
Drug: Crizotinib 250
RxNorm normalized name: crizotinib 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crizotinib 250 mg orally twice daily
Trial: 34214095
Drug: Rotasiil (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotasiil (3 doses)
Trial: 36069871
Drug: Litifilimab 450
RxNorm normalized name: Litifilimab
DrugBank: Litifilimab (DB18864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Litifilimab 450 mg
Trial: 35075494
Drug: Ningmitai capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ningmitai capsule (1.52 g, three times daily)
Trial: 34325077
Drug: Control group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group: resin-modified glass ionomer restoration with no treatment
Trial: 35694924
Drug: Olfactory training
RxNorm normalized name: BOS TAURUS OLFACTORY BULB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olfactory training (frequent short-term sniffing various odors) for 4 months, performed twice a day
Trial: 32272284
Drug: Omalizumab 150
RxNorm normalized name: omalizumab 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omalizumab 150 mg stepped up to 300 mg
Trial: 35694107
Drug: FES+MT training
RxNorm normalized name: Slow-Fe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FES+MT training (Functional Electrical Stimulation combined with Mirror Therapy)
Trial: 35694107
Drug: MT training
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MT training (Mirror Therapy)
Trial: 33938678
Drug: e‐pQLB (0.375%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: e‐pQLB (0.375% ropivacaine + 100 mcg epinephrine, 20 mL each side)
Trial: 33938678
Drug: pQLB (0.375%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pQLB (0.375% ropivacaine alone, 20 mL each side)
Trial: 35574691
Drug: TQC3564 single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQC3564 single ascending dose (SAD) 25 to 1200 mg
Trial: 35574691
Drug: TQC3564 multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQC3564 multiple ascending dose (MAD) 100 or 500 mg, QD
Trial: 35574691
Drug: TQC3564 food-effect
RxNorm normalized name: Allergenic extract, food, wheat
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQC3564 food-effect study 300 mg
Trial: 33928916
Drug: KCONVAC 5
RxNorm normalized name: COV-2 COVID-19 Inactivated Non-US Vaccine Product (Minhai Biotechnology Co, KCONVAC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KCONVAC 5 μg/dose
Trial: 33928916
Drug: KCONVAC 10
RxNorm normalized name: COV-2 COVID-19 Inactivated Non-US Vaccine Product (Minhai Biotechnology Co, KCONVAC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KCONVAC 10 μg/dose
Trial: 33928916
Drug: KCONVAC 5
RxNorm normalized name: COV-2 COVID-19 Inactivated Non-US Vaccine Product (Minhai Biotechnology Co, KCONVAC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KCONVAC 5 μg/dose (0/14 regimen)
Trial: 33928916
Drug: KCONVAC 10
RxNorm normalized name: COV-2 COVID-19 Inactivated Non-US Vaccine Product (Minhai Biotechnology Co, KCONVAC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KCONVAC 10 μg/dose (0/14 regimen)
Trial: 33928916
Drug: KCONVAC 5
RxNorm normalized name: COV-2 COVID-19 Inactivated Non-US Vaccine Product (Minhai Biotechnology Co, KCONVAC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KCONVAC 5 μg/dose (0/28 regimen)
Trial: 33928916
Drug: KCONVAC 10
RxNorm normalized name: COV-2 COVID-19 Inactivated Non-US Vaccine Product (Minhai Biotechnology Co, KCONVAC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KCONVAC 10 μg/dose (0/28 regimen)
Trial: 34666273
Drug: bilateral STN-DBS
RxNorm normalized name: DB-OTO
DrugBank: DB-OTO (DB18278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bilateral STN-DBS plus optimal drug therapy (ODT)
Trial: 34666273
Drug: optimal drug
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: optimal drug therapy (ODT) alone
Trial: 36296994
Drug: 24 g
RxNorm normalized name: glucose 24 g/31 g oral gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 g of fiber/day from 2 buns of 12 g each
Trial: 36296994
Drug: 12 g
RxNorm normalized name: PEG-12 GLYCERYL LAURATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 g of fiber/day from 2 buns of 6 g each
Trial: 34371825
Drug: Culinary education
RxNorm normalized name: Lens culinaris fruit extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culinary education through 12 weekly 30-min one-on-one telemedicine culinary coaching sessions
Trial: 34116166
Drug: Infants reared
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infants reared by biological mothers (n = 113)
Trial: 33836153
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg intravenously every 3 weeks for up to 35 cycles
Trial: 35385794
Drug: Mebendazole 500
RxNorm normalized name: mebendazole 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mebendazole 500 mg orally BID for 12 weeks
Trial: 32673356
Drug: 80 kVp,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 kVp, 320 mgl/ml CM at 4 ml/s (Group B)
Trial: 32673356
Drug: 80 kVp,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 kVp, 320 mgl/ml CM at 5 ml/s (Group C)
Trial: 32673356
Drug: 100 kVp,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 kVp, 400 mgl/ml CM at 4 ml/s (Group A)
Trial: 33338971
Drug: alprazolam (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alprazolam (1.5 mg daily for 5 days)
Trial: 33338971
Drug: etifoxine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etifoxine (150 mg daily for 5 days)
Trial: 35020462
Drug: Dextroamphetamine Transdermal
RxNorm normalized name: dextroamphetamine Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine Transdermal System (d-ATS) 5 mg patch applied for 9 hours
Trial: 35020462
Drug: Dextroamphetamine Transdermal
RxNorm normalized name: dextroamphetamine Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine Transdermal System (d-ATS)
Trial: 34706706
Drug: Spinal manipulative
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal manipulative therapy and home stretching exercises
Trial: 32048379
Drug: Continuous positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous positive airway pressure (CPAP) treatment for 6 months
Trial: 33095213
Drug: Supramolecular ligand
RxNorm normalized name: Gallium Ga 68-labeled psma ligand Glu-urea-Lys(ahx)-hbed-CC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supramolecular ligand from the drug-candidate library
Trial: 32868356
Drug: Pharmacy intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmacy intervention pathway - rapid point-of-care HCV PCR test and direct-acting antivirals (DAAs) delivered via pharmacist.
Trial: 33978823
Drug: Glasdegib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glasdegib plus low-dose cytarabine
Trial: 34215599
Drug: LDL-C ≥1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-C ≥1.8 mmol/L
Trial: 37034344
Drug: LDL-C <1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-C <1.8 mmol/L
Trial: 32888011
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of treatment recommendation based on anatomical SYNTAX score (SS) between sites and CL
Trial: 32888011
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of treatment recommendation based on functional SYNTAX score (SS) between sites and CL
Trial: 36177759
Drug: Physical therapist-led
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapist-led care (personalized hip therapy)
Trial: 32465861
Drug: Aspirin (ASA)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (ASA) 81 mg daily
Trial: 33321452
Drug: NTCELL® administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTCELL® administration (putaminal encapsulated porcine choroid plexus cells)
Trial: 35018643
Drug: Esketamine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esketamine (0.2 mg/kg)
Trial: 32615613
Drug: 2×20 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2×20 g carbohydrates (muesli bars)